Rafael Holdings, Inc. Class B (RFL): Price and Financial Metrics

Rafael Holdings, Inc. Class B (RFL): $1.74

0.02 (-1.14%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

F

RFL Price/Volume Stats

Current price $1.74 52-week high $2.52
Prev. close $1.76 52-week low $1.44
Day low $1.73 Volume 6,900
Day high $1.84 Avg. volume 25,179
50-day MA $1.75 Dividend yield N/A
200-day MA $1.89 Market Cap 42.78M

RFL Stock Price Chart Interactive Chart >


Rafael Holdings, Inc. Class B (RFL) Company Bio


Rafael Holdings, Inc., through its subsidiary, manufactures metabolic oncology drugs to treat cancer. The company also owns and operates real estate properties. The company was incorporated in 2017 and is based in Newark, New Jersey. Rafael Holdings, Inc. operates as a subsidiary of IDT Corporation


RFL Latest News Stream


Event/Time News Detail
Loading, please wait...

RFL Latest Social Stream


Loading social stream, please wait...

View Full RFL Social Stream

Latest RFL News From Around the Web

Below are the latest news stories about RAFAEL HOLDINGS INC that investors may wish to consider to help them evaluate RFL as an investment opportunity.

Rafael Holdings GAAP EPS of -$0.15, revenue of $68K

More on Rafael Holdings

...

Seeking Alpha | December 14, 2023

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investmentsNEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023. “During fiscal 2024, we will continue to focus on advancing our existing portfolio and identifying strategic investments in companies which have the pot

Yahoo | December 14, 2023

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

GAINESVILLE, Fla., November 15, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023.

Yahoo | November 15, 2023

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunitiesNEWARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and full year of fiscal 2023 - the three and twelve months ended July 31, 2023. “During fiscal 2023, we made meaningful progress toward expanding our portfolio through strategic investments in companies which have th

Yahoo | October 30, 2023

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

GAINESVILLE, Fla., August 15, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2023.

Yahoo | August 15, 2023

Read More 'RFL' Stories Here

RFL Price Returns

1-mo 1.75%
3-mo -1.14%
6-mo 15.23%
1-year -16.35%
3-year -95.69%
5-year -89.23%
YTD -4.92%
2023 -2.14%
2022 -63.33%
2021 -78.13%
2020 30.72%
2019 124.97%

Continue Researching RFL

Want to see what other sources are saying about Rafael Holdings Inc's financials and stock price? Try the links below:

Rafael Holdings Inc (RFL) Stock Price | Nasdaq
Rafael Holdings Inc (RFL) Stock Quote, History and News - Yahoo Finance
Rafael Holdings Inc (RFL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!